Mr. Witteveen is shedding light on impactful changes to bolster AegirBio's market position. The presentation provides an understanding of AegirBio's customer-centric, innovation-driven future.
"We're at an exciting juncture in AegirBio's journey," remarked Mr. Witteveen. "The enhancements lay the foundation for a more business driven organization. This presentation is a testament to our commitment to transparency and a preview of the dynamic future we're building together."
AegirBio is a Swedish diagnostics company founded in 2019 to offer tests to monitor and optimize the dosage of biological drugs via its unique patented technology platform. In June 2020, AegirBio was listed on the Nasdaq First North Growth Market. The company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and to provide accurate and easily transferable results. For more information, see Aegirbio's website www.aegirbio.com
The company's Certified Adviser is Eminova Fondkomission AB | 08-684 211 00 | firstname.lastname@example.org